|| Print ||
|Archives - April 2008|
|Tuesday, April 01, 2008|
Tiny, stainless steel lattice tubes have been propping coronary arteries open since the 1980s, but never without triggering reactions in some patients that are worse than untreated heart disease. In 2001, scientists began coating stents with drugs to help prevent heart attack-inducing blood clots. But 30,000 out of the 6 million patients worldwide who receive them still die. “Metal is inherently not biocompatible,” says Dr. Kenton Gregory, director of Oregon Medical Laser Center at Providence St. Vincent Medical Center in Portland. More than a decade ago, Gregory decided he needed to go back to nature if stent technology was to move forward. Gregory, whose work at the center has received 22 patents and $25 million in grants, developed a coating modeled after the artery wall’s own lining: a protein called elastin. As the name suggests, the protein stretches without breaking and molds well to any object it coats, even metal tubes 1.5 mm in diameter and 12 mm in length. Most importantly, the body won’t reject it. Gregory and his team at OMLC completed tests on domestic pigs last fall with “extremely successful” results and plan to start human trials in Brazil later this year. Once the design gets FDA approval — Gregory expects within two years — he’ll begin marketing the new device in hopes that this “metal, human-protein hybrid” will succeed where lesser stents have failed. Lives saved by listening to nature. EVAN CAEL
Wednesday, August 20, 2014
By Kim Moore | OB Editor
The 2015 survey launched this week. It is open to for-profit private and public companies that have at least 15 full- or part-time employees in Oregon.
Wednesday, August 27, 2014
BY LINDA BAKER
Dr. Chong Fang isn’t God. But the assistant professor of chemistry at Oregon State University is getting closer to figuring out how he put everything together.
Tuesday, August 19, 2014
BY TOM COX | OB BLOGGER
Tom Cox interviews Steve Balzac, author of "Organizational Psychology for Managers."
Friday, July 18, 2014
BY JASON NORRIS | OB GUEST CONTRIBUTOR
Back in May, we shared a common Wall Street quote about investing, “Sell in May and go away.” Fast forward to July and the most common question we have been getting from clients is, “When is the market pullback going to occur?”
Tuesday, August 26, 2014
Parents and students paying for college today are like homeowners who bought a house just before the housing bubble burst.
Friday, August 15, 2014
In this week's poll, we asked readers: "Who should pay for the troubled Cover Oregon website?" Here are the results.
Wednesday, August 27, 2014
Kim Ierian, President of Concorde Career Colleges, and Deborah Edward, Executive Director of Business for Culture & the Arts, share their recent reads.
|The Private 150: Bigger But Leaner|
|The Perfect Food|
|Powerlist: Staffing Firms|
|Taxis Uber Alles?|
|Halliburton to pay $1.1B to settle lawsuits|
|U.S. eating habits improve, except among poor|
|Google tests drone deliveries|
|Abercrombie to remove logos from most clothing|
|FBI investigates JPMorgan 'cyber-attack'|
|GoPro launches camera dog harnesses|
|Snapchat now worth $10B|
First Call Resolution targets employee well-being and client satisfaction.
How six leading foundations are working together for a better Oregon.
Vigilant enters a New Year with a new president.
Lane Powell Shareholder William T. Patton has been appointed to the board of directors for Cascade AIDS Project, an organization that provides educational services and outreach to thousands of Oregonians living with HIV/AIDS.
Fifty-one Lane Powell lawyers were recently selected by their peers for inclusion in The Best Lawyers in America® (Best Lawyers) 2015; of those selected, 23 lawyers are from the Firm’s office in Portland, Oregon.
Barran Liebman is proud to announce that Andrew Schpak, a Partner of the firm, has been named Chair of the American Bar Association’s Young Lawyers Division for the 2014-2015 bar year.